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Abstract 
Background: Breast incidental lesion at 18 F FDG PET/CT are occasionally encountered in cancer patients, 
which may represent a second primary malignancy. The aim of the present study was to investigate the 
diagnostic performance of PET metabolic parameters to characterize breast incidentaloma. 
Materials and Methods: All the images of patients with cancers other than breast with breast incidental lesion 
underwent PET/CT scan at Masih Daneshvari Hospital between May 2012 and May 2016 were retrieved and 
reviewed. SUVmax, SUVmean, MTV and TLG in addition to associated morphologic features on CT and 
demographics were recorded and correlated with final diagnosis defined by histophatologic confirmation or an 
at least 1-year clinical formal follow up. 
Results: Of a total 58 from 51 patients (51/5029, 1.01%), 10 (19.60%) were histopathologically verified as 
second primary breast cancers. There was a statistically significant difference in SUVmax, SUVmean, MTV 
and TLG between benign and malignant group (1.64 vs. 5.32 (p=0.009), 1.34 vs. 3.69 (p=0.027), 0.96 vs. 
2.62 (p=0.035), 1.54 vs 8.89 (p=0.006). Using cut off 2, 1.35, 1.16 and 1.75, sensitivity and specificity of 
SUVmax, SUVmean, MTV and TLG were calculated as 77% and 62%, 92% and 66.5%, 77% and 75% 77% 
and 67%, respectively. 
Conclusion: Despite a significantly higher value in malignant breast incidental lesion, PET-derivative 
metabolic parameters provided only modest sensitivity and specificity and hence may not be considered as the 
sole criteria for risk stratification in this clinical setting. 
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Introduction 
Breast incidental lesions are occasionally encountered 
at 18 F FDG PET/CT scan harboring malignancy in 
up to 57% of cases
1
. Accurate risk stratification of 
breast incidentaloma may prompt further diagnostic 
work up to avoid delayed urgent treatment. Recent 
investigations have provided evidence for PET-
derived metabolic parameters as reliable prognostic 
indicators in various malignancies. SUVmax as the 
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most validated semi quantitative PET-based measures 
play a major role in the diagnostic algorithm of 
solitary pulmonary nodule with an excellent 
diagnostic performance (sensitive=97%, 
specific=85%, positive predictive value=93%, 
negative predictive value=92%, accuracy=93%)
2
; 
However, diagnostic applications of these parameters 
still needs to be verified in routine practice in most 
clinical settings. Few publications have investigated 
the potential role of metabolic parameters in 
differentiation of malignant from benign conditions 
identified at 18 F FDG PET/CT. One study provided 
evidence for SUVmax and TLG as a useful predictor 
of malignancy in intermediate and high-risk adrenal 
incidentaloma
3
. Another study demonstrated that PET 
metabolic parameters offer the potential to accurately 
identify malignant mediastinal tumor
4
. Evidence of 
ovarian tumoral lesions was also encouraging
5
. 
Many studies have been reported the prevalence and 
clinical significance of the breast incidental lesion at 
18 F FDG PET/CT
1,6-8
; however, few have been 
investigated the potential value of metabolic 
parameters for characterization and risk stratification 
of breast incidental lesion
1,8
. To the best of our 
knowledge, there is little evidence of potential 
diagnostic value of volumetric PET-derivative 
metabolic parameters in breast incidentaloma. The 
aim of the present study was to investigate the 
diagnostic performance of SUVmax, SUVmean, 
MTV and TLG in association with other 
demographics, underlying cancer related 
characteristics and CT-associated morphologic 
features in breast incidentaloma in patients with non-
breast cancers. 
Methods 
The Institutional Review Board at Shahid Beheshti 
University of Medical Science approved this 
retrospective study and waived the need for informed 
consent.  
Patients: Of a total 5826 cancer patients investigated 
by
18 
F FDG-PET/CT at Masih Daneshvari Hospital, 
as a tertiary teaching center of PET/CT, from May 
2012 to May 2016, 5029 patients were identified to 
have non-breast cancer. A retrospective review of 
PET reports revealed 72 breast incidental lesions in 
68 patients for further analysis. Of these, 10 patients 
lost to complete clinical formal follow up and 3 were 
not candidates for histopathologic examination due to 
advanced primary cancer and hence were excluded 
from the study. Lesions with a mean diameter below 
the PET resolution (7mm) were also excluded due to 
the negative impact of partial volume effect on the 
accuracy of PET-derived metabolic information 
(n=4). Finally, a total of 51 patients with 56 lesions 
constituted the study cohort. Demographics and 
primary cancer characteristics, including age, gender 
and type of primary cancer were recorded for each 
patient. 
Imaging Acquisition and FDG-PET/CT acquisition 
protocol: Whole body F-18 FDG PET/CT was 
performed using an integrated FDG-PET/CT scanner 
(GE 690 Discovery, 64 Slice, Time of Flight). Fasting 
period was considered at least 8hr. Blood glucose 
level was below 150 mg/dl at the time of radiotracer 
injection. Sixty minutes (±10%) after 4.6MBq/Kg 
(0.12 mCi/Kg) IV administration of 2-deoxy- 2-[ 18 
F]fluoro -D-glucose (F FDG)
18
, CT acquisition 
commenced craniocuadally in supine position from 
vertx to mid-thigh (or to toe as indicated) with a 
multidetector CT scanner and the following 
parameters: 50-120 auto mAs tube current, 120 kV, 
noise factor 19, 2.5 mm thickness, tidal breathing. 
Thirty minutes before imaging acquisition, 40cc 
meglumin 76% (containing 370mg Iodine /cc) in 
1500 water was administered as oral contrast. The 
PET data were then collected in the reverse direction 
immediately after CT acquisition at 3 minutes per bed 
position. The PET raw data were corrected for 
attenuation, dead time, random and scatter 
coincidence, and subsequently reconstructed by 
iterative method and HD (high definition) technique.  
Image interpretation FDG PET/CT: All PET 
images’ data set of eligible cohort were retrieved and 
reviewed at volume share AW 4.5 (Advantage 
Windows: GE, 690) by a team comprised of an 
experienced radiologist and a nuclear physician 
reached in consensus for visual interpretation of 
abnormal breast findings. Abnormal increased 18F 
FDG uptake in the breast more than background 
activity of surrounding normal tissue on AC and Non-
AC PET images and/or abnormal soft tissue density 
including nodule, skin thickening or ill-defined soft 
tissue density on CT images were considered as breast 
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incidental finding. The greatest axial diameter of the 
CT corresponding abnormality was measured (in 
mm). The intensity of FDG uptake was categorized as 
mild (equal or less than mediastinal blood pool 
activity), moderate (more than a mediastinal blood 
pool and equal or less than liver activity) and severe 
(markedly more than liver activity) for descriptive 
purposes. To define as a dichotomous diagnostic test, 
lesion intensity of 18F FDG was reclassified as non to 
moderate uptake and intense uptake, representative of 
benign and malignancy, respectively. 
Metabolic parameters were calculated semi 
automatically on PETVCAR AW 4.5. A volume of 
interest was drawn on the metabolically active breast 
lesion. SUVmax , as the most validated easily 
obtainable PET Semiquantitative metabolic 
parameters were then measured and recorded.  
Standard of reference: All breast incidental lesions 
were finally verified as benign or malignant according 
to the histological findings or oncologist decision 
making based on a at least 1-year clinical formal 
follow up including routine clinical examination and 
serial breast US and mammography as well as follow 
up PET/CT whenever available as the standard of 
reference. Tissue biopsy was obtained in 20 patients 
(43.13%) (Fine needle, n=12, excisional biopsy, n=8) 
immediately after baseline breast imaging and the 36 
remaining (56.86%) underwent clinical formal follow 
up (median follow up duration=24.18 months). Two 
patients developed histologically-proven malignant 
lesions 9 and 6 months after the benign baseline US 
examinations categorized as BI-RDAS II and BI-
RADS III, respectively. Thirty four lesions revealed 
no further evidence of malignant nature by the end of 
the study and thus considered as a benign lesion in 29 
patients. 
Statistical analysis: Normally and non-normally 
distributed variables were analyzed by parametric and 
nonparametric tests, respectively. Continuous and 
categorical variables were described as mean±SD and 
frequency and compared between benign and 
malignant groups using Mann-Whitney U-test and the 
Fisher exact test with linear-by-linear association, 
respectively. Receiver operating characteristic (ROC) 
curves were performed to investigate the diagnostic 
characteristics of the SUVmax, SUVmean, MTV and 
TLG for identification of malignancy based on the 
appropriate cutoff. All statistical analysis was 
performed using SPSS version 23. 
Results 
Fifty one out of 5029 patients (1.01%) with a total of 
Table 1: Quantitative metabolic parameters of PET-detected breast incidental lesions. 








Benign Lesions 1.64 (±1.01) 1.34 (±0.9) 0.96 (±0.6) 1.54 (±1.12) 
 Fibroadenoma 
4.64  (±2.44) 3.37  (±2.14) 1.29  (±.80) 4.17 (±3.22) 
Not otherwise 
specified 2.36 (±1.13) 1.8 (±.92) 1.28 (±1.77) 2.98 (±1.99) 
Malignant Lesion 5.32 (±2.23) 3.69 (±1.67) 2.62 (±1.61) 8.89 (±5.34) 
 Invasive Ductal 
Carcinoma 6.76 (±4.36) 4.66 (±2.67) 2.52 (±2.75) 10.89 (±12.16) 
Invasive lobular 
carcinoma 1.26 (±1.13) .93 (± .80) 3.1 (±5.16) 4.34 (±7.23) 
Lymphoma 
8.8 6.1 1.78 10.8 
*SUV= Maximum Uptake Value 
**MTV=Metabolic Tumor Volume 
***TLG=Total Lesion Glycolysis 
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56 lesions were identified to have breast incidental 
lesions (48 female (94.1%), 3 male (5.9%), mean age: 
49.18±14.31, age range: 17-71 years old). The 
prevalence of the underlying cancers were as the 
following: Lymphoma (HD and NHL): 15 (29.4%), 
Genitourinary: 15 (29.5%), GI (esophageal, gastric 
and colon cancer) 9 (17.7%), lung cancer 5 (9.8%), 
head and neck cancer 2 (3.9%), osteosarcoma 1 
(1.9%), chondrosarcoma 1 (1.9%), non-melanoma 
skin tumor 1 (1.9%), plasmacytoma 1 (2%) and 
papillary thyroid carcinoma 1 (2%).  
Of a total 56 lesions, 47 (83.92%) in 41 patients 
 
 
Figure 1. Invasive ductal carcinoma incidentally detected in a 66 Y/O women with endometrial cancer being work up for subsequent 
treatment strategy. MIP (a), PET, NECT and fused PET/CT in axial view (b-d) demonstrated a small focus of intense F-18 FDG uptake 




Figure 2. Fibroadenoma incidentally detected in a 68 Y/O women with ovarian cancer being work up for subsequent treatment strategy. 
MIP (a), PET, NECT and fused PET/CT in axial view (b-d) demonstrated focal intense F-18 FDG uptake corresponding with a calcified 
irregular isodense soft tissue density in right breast. 
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ultimately proved to be of benign origin, 12 (25.53%) 
by histopathologic confirmation (fibrocystic change 
[n=5], fibroadenoma [n=4], intraductal papilloma 
[n=3]) and 36 (74.46%) by a mean duration of 24.18 
month clinical formal follow up. Among 10 
histologically-verified malignant lesions (19.6%), 3 
subtypes were classified: invasive ductal carcinoma 
(n=6), invasive lobular carcinoma (n=3) and 
lymphoma (n=1). 
There was no statistically significant difference 
between benign and malignant groups regarding mean 
age (49.25 years old [17-77] vs 48.88 years old [30-
66], p=0.9) and gender (benign lesions: 39 female 
[95.12%] vs 2 male [4.78%], malignant lesion: female 
9 [90%], male 1 [10%], p=0.53). Genitourinary 
malignancies constituted the vast majority of primary 
cancers in the malignant group (n=6/9, 60%) which 
was more prevalent compared to the benign cohort 
 
 
Figure 3. Invasive lobular carcinoma incidentally detected in a 57 Y/O women with colon cancer being work up for subsequent treatment 
strategy. MIP (a), PET, NECT and fused PET/CT in axial view (b-d) demonstrated a partially calcified irregular mass in right breast with no 




Figure 4. ROC curves for PET-metabolic parameters for the detection of malignant lesion in patients breast incidental lesions at 18F FDG 
PET/CT. 
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(9/41, 21.95%) though not statistically significant 
(p=0.10).  
CT corresponding features showed significant 
difference between study groups. Nodule was 
demonstrated as the unique associated morphological 
abnormality of malignant lesions which was 
significantly more prevalent compared to benign 
group (60.5%) (p=0.04). There was a trend toward a 
greater mean diameter of malignant nodules, 
however, the difference did not approach a statistical 
significance (14.37 vs. 19.61 mm, p=0.060). Other 
structural abnormalities in benign group were ill-
defined soft tissue density (n=12, 31.6%) and skin 
thickening (n=3, 7.9%). 
Regarding the anatomic location, most benign and 
malignant lesions were found in UUQ (61.5% vs. 
80%), followed by UIQ (20.5% vs. 10%), LOQ (5.1% 
vs. 10%) and LIQ (12.8% vs. 0), respectively. The 
laterality distribution pattern was found to be as the 
following: 25 (49%) on the right, 21 (41.17%) on the 
left and 5 (9.8%) bilateral. Most malignant lesions 
were found in right breast (70% vs 30%) while benign 
lesions showed equal distribution between right and 
left side (right side: n=18 [43.3%], left side: n= 18 
[43.3%]) 
In the context of metabolic criteria, the intensity 
pattern of FDG uptake significantly differed between 
benign and malignant groups (P=0.000). Two out of 
41 benign lesions (4.8%) vs. 6 out of 10 (60%) 
malignant lesions demonstrated severe FDG uptake, 
the difference of which proved to be statistically 
significant (p=0.000). Sizable lesions (>7mm) with no 
discernible metabolic activity were found in 11 
benign lesions (26.8%) and 1 pathologically-
diagnosed malignant lesion (10%). 
Focal pattern of FDG uptake was found in 28/41 
(75.7%) of benign lesions and 10/10 (100%) of 
malignant lesions (p value=0.05).  
On the basis of histologic subtypes, metabolic 
characteristics of invasive ductal carcinoma (Figure 1) 
and 3 histologically-proven fibroadenoma (Figure 2) 
did not show significant differences (p value for 
intensity of 
18
F FDG uptake, SUVmax were 0.1 and 
0.42, respectively). In addition, no significant 
difference was found between metabolic features of 
invasive lobular carcinoma (Figure 3) and not 
otherwise specified begins lesions (p value for 
intensity uptake and SUVmax were 0.1 and 0.91, 
respectively).  
All PET metabolic parameters including SUVmax, 
SUVmean, MTV and TLG demonstrated statistically 
significant differene between benign and malignant 
groups Table 1 summarized metabolic characteristics 
of breast incidental lesion in benign and malignant 
groups as well as on a per histologic types. There was 
no statistically significant difference between 
metabolic parameters of invasive ductal carcinoma 
and fibarodenoma (p value for SUVmax, SUVmean, 
MTV and TLG were 0.52, 0.40, 0.46, 0.25, 
respectively). In addition, no significant difference 
was found between invasive lobular carcinoma and 
begins lesions other than fibroadenoma (p value for 
SUVmax, SUVmean, MTV and TLG were 0.91, 0.75, 
0.75, 0.79, respectively). Figure 4 demonstrated the 
area under the ROC curve as 0.78 (p=.003) for 
SUVmax, 0.75 (p=.006) for SUVmean, 0.75 (p=.005) 
for MTV and 0.8 (p=.001) for TLG. The sensitivity 
and specificity for detection of malignant lesion using 
SUVmax of 2 were 77% and 62.5%, SUVmean of 
1.35 were 92% and 52.5%, MTV of 1.16 were 77 and 
75% and TLG of 1.75 were 77 and 67%, respectively. 
Discussion 
Current study revealed that PET-derivative metabolic 
parameters showed significantly higher values in the 
malignant  lesion compared to benign ones, though 
the diagnostic performance seemed to be modest. 
Most researches have focused on the prognostic 
implications of PET metabolic parameters
9-13
 but 
evidence on their diagnostic performance, particularly 
of volumetric measures including MTV and TLG for 
detection of malignancy is scarce. The results of one 
study
4
 demonstrated that in mediastinal tumor 
SUVmax=4.2 has a sensitivity, specificity, positive 
predictive value, negative predictive value and 
accuracy of 78.2%, 86.2%, 82.6%, 81.8% and of 
83.3% to identify malignancy, respectively. 
Volumetric metabolic parameters showed a better 
performance since MTV of 22.3 and TLG of 79.9 
revealed sensitivity, specificity, accuracy, positive 
predictive value and negative predictive value of 
82.6%, 96.6%, 90.4%, 95%, and 87.5%, respectively 
to distinguish benign from malignant mediastinal 
tumor. In this study, metabolic parameters of thymic 
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carcinoma demonstrated significantly higher values in 
comparison with thymoma and hence it was 
concluded that PET-derivative metabolic parameters 
may be considered as an accurate predictor of 
malignancy in mediastinal tumor. In another study on 
adrenal incidentaloma
3
 malignant lesions 
demonstrated significantly higher values of metabolic 
parameters when compared to benign lesions. Using a 
cutoff of 12, TLG showed a sensitivity and specificity 
of 92.1% and 78.6%, respectively. The author 
concluded that TLG may be a reliable indicator of 
malignancy in adrenal incidentaloma. One study 
demonstrated that mean SUVmax, SUVmean and 
TLG of malignant ovarian masses are significantly 
higher than benign lesions (7.55 and 4.17, p<0.001, 
4.5 and 2.5, p<0.001, 302.196 and 130.458, p=0.035) 
and hence, concluded that metabolic indices at 18F 
FDG PET/CT in association with visual interpretation 
criteria may be useful to detect malignant ovarian 
lesion
5
. However, in an attempted to differentiate 
borderline ovarian tumors and stage 1malignant 
ovarian tumor
14
, one study suggested that cystic 
portion of malignant ovarian tumor may negatively 
influence on the ability of volumetric measures, 
including MTV and TLG to predict malignancy and 
recommended that mean SUVmax should be 
considered as the most reliable discriminator of 
malignancy in this clinical setting (2.9±1.5 vs. 
6.6±2.9, p=0.02) with a high sensitivity and 
specificity (using a cutoff of 3.7, 83.3% and 85.7%, 
respectively). On the contrary, researches on 
diagnostic performance of SUVmax to differentiate 
benign and malignant breast incidental lesion was 
discouraging. A recent study on 60 patients with 
breast incidentaloma revealed that using a cutoff of 
2.3, SUVmax had a sensitivity and specificity of 
61.3% and 76.3%, respectively to identify malignant 
lesion
6
. In another study of 48 patients, including 
62.5% benign lesions and 37.5% malignant lesions, 
the optimal cutoff for SUVmax was found to be 2
7
. 
One research on 91 breast incidental lesions (70.3% 
benign and 29.7% malignant lesions) demonstrated a 
significant difference in median SUVmax of benign 
and malignant lesions, but with a significant overlap 
in the range of SUVmax between benign and 
malignant groups (1.3-16 vs.1-5.7, respectively) and 
hence concluded that SUVmax should not be 
considered as a reliable index to differentiate benign 
from malignant breast incidentaloma
8
. In one research 
SUVmax between benign and malignant lesions 
showed a borderline significant difference (0.054)
1
. In 
line with literature, the results obtained in the current 
study showed a significant different in all PET-
derivative metabolic parameters between benign and 
malignant lesions; however, the overall diagnostic 
performance was suboptimal. This can be explained 
by the distinct metabolic characteristics of 
fibroadenoma which may demonstrate a high level of 
metabolic activity and consequently mimic invasive 
ductal carcinoma. Regarding low cellular density and 
infiltrative growth pattern, invasive lobular carcinoma 
may be considered as a potential source of false 
negative and relatively low sensitivity of PET/CT to 
evaluate breast incidental lesion. Such finding are 
compatible with the results of previous studies, which 
demonstrated a significant overlap between metabolic 




There are some drawbacks in the present study. 
Histopathologic confirmation was not available for all 
breast incidental lesions. Sonographic/mammographic 
assessment of breast incidentaloma was performed 
outside the clinic. Small sized cohort preclude precise 
characterization of metabolic features in each 
histological subtype. 
Conclusion 
PET-derivative metabolic parameters showed 
significantly higher value in malignant lesion 
compared to benign disease, however, due to the 
distinct metabolic features of invasive lobular 
carcinoma and fibroadenoma, as the major potential 
sources of falsely negative malignant lesion and 
falsely positive, benign ones at 18 F FDG PET/CT, 
metabolic measures do not serve as a reliable 
indicator for risk stratification of breast incidental 
lesion. 
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